Profitability ratios measure the company ability to generate profitable sales from its resources (assets).
Paying user area
Try for free
Vertex Pharmaceuticals Inc. pages available for free this week:
- Analysis of Long-term (Investment) Activity Ratios
- Common Stock Valuation Ratios
- Enterprise Value (EV)
- Dividend Discount Model (DDM)
- Return on Equity (ROE) since 2005
- Current Ratio since 2005
- Debt to Equity since 2005
- Total Asset Turnover since 2005
- Price to Earnings (P/E) since 2005
- Price to Operating Profit (P/OP) since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Vertex Pharmaceuticals Inc. for $22.49.
This is a one-time payment. There is no automatic renewal.
We accept:
Profitability Ratios (Summary)
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
Profitability ratio | Description | The company |
---|---|---|
Gross profit margin | Gross profit margin indicates the percentage of revenue available to cover operating and other expenditures. | Vertex Pharmaceuticals Inc. gross profit margin ratio deteriorated from 2021 to 2022 and from 2022 to 2023. |
Operating profit margin | A profitability ratio calculated as operating income divided by revenue. | Vertex Pharmaceuticals Inc. operating profit margin ratio improved from 2021 to 2022 but then slightly deteriorated from 2022 to 2023 not reaching 2021 level. |
Net profit margin | An indicator of profitability, calculated as net income divided by revenue. | Vertex Pharmaceuticals Inc. net profit margin ratio improved from 2021 to 2022 but then slightly deteriorated from 2022 to 2023. |
Profitability ratio | Description | The company |
---|---|---|
ROE | A profitability ratio calculated as net income divided by shareholders’ equity. | Vertex Pharmaceuticals Inc. ROE improved from 2021 to 2022 but then deteriorated significantly from 2022 to 2023. |
ROA | A profitability ratio calculated as net income divided by total assets. | Vertex Pharmaceuticals Inc. ROA improved from 2021 to 2022 but then deteriorated significantly from 2022 to 2023. |
Gross Profit Margin
Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | ||||||
Gross profit | ||||||
Revenues | ||||||
Profitability Ratio | ||||||
Gross profit margin1 | ||||||
Benchmarks | ||||||
Gross Profit Margin, Competitors2 | ||||||
AbbVie Inc. | ||||||
Amgen Inc. | ||||||
Bristol-Myers Squibb Co. | ||||||
Danaher Corp. | ||||||
Eli Lilly & Co. | ||||||
Gilead Sciences Inc. | ||||||
Johnson & Johnson | ||||||
Merck & Co. Inc. | ||||||
Moderna Inc. | ||||||
Pfizer Inc. | ||||||
Regeneron Pharmaceuticals Inc. | ||||||
Thermo Fisher Scientific Inc. |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
1 2023 Calculation
Gross profit margin = 100 × Gross profit ÷ Revenues
= 100 × ÷ =
2 Click competitor name to see calculations.
Profitability ratio | Description | The company |
---|---|---|
Gross profit margin | Gross profit margin indicates the percentage of revenue available to cover operating and other expenditures. | Vertex Pharmaceuticals Inc. gross profit margin ratio deteriorated from 2021 to 2022 and from 2022 to 2023. |
Operating Profit Margin
Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | ||||||
Income from operations | ||||||
Revenues | ||||||
Profitability Ratio | ||||||
Operating profit margin1 | ||||||
Benchmarks | ||||||
Operating Profit Margin, Competitors2 | ||||||
AbbVie Inc. | ||||||
Amgen Inc. | ||||||
Bristol-Myers Squibb Co. | ||||||
Danaher Corp. | ||||||
Eli Lilly & Co. | ||||||
Gilead Sciences Inc. | ||||||
Johnson & Johnson | ||||||
Merck & Co. Inc. | ||||||
Moderna Inc. | ||||||
Pfizer Inc. | ||||||
Regeneron Pharmaceuticals Inc. | ||||||
Thermo Fisher Scientific Inc. | ||||||
Operating Profit Margin, Sector | ||||||
Pharmaceuticals, Biotechnology & Life Sciences | ||||||
Operating Profit Margin, Industry | ||||||
Health Care |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
1 2023 Calculation
Operating profit margin = 100 × Income from operations ÷ Revenues
= 100 × ÷ =
2 Click competitor name to see calculations.
Profitability ratio | Description | The company |
---|---|---|
Operating profit margin | A profitability ratio calculated as operating income divided by revenue. | Vertex Pharmaceuticals Inc. operating profit margin ratio improved from 2021 to 2022 but then slightly deteriorated from 2022 to 2023 not reaching 2021 level. |
Net Profit Margin
Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | ||||||
Net income | ||||||
Revenues | ||||||
Profitability Ratio | ||||||
Net profit margin1 | ||||||
Benchmarks | ||||||
Net Profit Margin, Competitors2 | ||||||
AbbVie Inc. | ||||||
Amgen Inc. | ||||||
Bristol-Myers Squibb Co. | ||||||
Danaher Corp. | ||||||
Eli Lilly & Co. | ||||||
Gilead Sciences Inc. | ||||||
Johnson & Johnson | ||||||
Merck & Co. Inc. | ||||||
Moderna Inc. | ||||||
Pfizer Inc. | ||||||
Regeneron Pharmaceuticals Inc. | ||||||
Thermo Fisher Scientific Inc. | ||||||
Net Profit Margin, Sector | ||||||
Pharmaceuticals, Biotechnology & Life Sciences | ||||||
Net Profit Margin, Industry | ||||||
Health Care |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
1 2023 Calculation
Net profit margin = 100 × Net income ÷ Revenues
= 100 × ÷ =
2 Click competitor name to see calculations.
Profitability ratio | Description | The company |
---|---|---|
Net profit margin | An indicator of profitability, calculated as net income divided by revenue. | Vertex Pharmaceuticals Inc. net profit margin ratio improved from 2021 to 2022 but then slightly deteriorated from 2022 to 2023. |
Return on Equity (ROE)
Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | ||||||
Net income | ||||||
Shareholders’ equity | ||||||
Profitability Ratio | ||||||
ROE1 | ||||||
Benchmarks | ||||||
ROE, Competitors2 | ||||||
AbbVie Inc. | ||||||
Amgen Inc. | ||||||
Bristol-Myers Squibb Co. | ||||||
Danaher Corp. | ||||||
Eli Lilly & Co. | ||||||
Gilead Sciences Inc. | ||||||
Johnson & Johnson | ||||||
Merck & Co. Inc. | ||||||
Moderna Inc. | ||||||
Pfizer Inc. | ||||||
Regeneron Pharmaceuticals Inc. | ||||||
Thermo Fisher Scientific Inc. | ||||||
ROE, Sector | ||||||
Pharmaceuticals, Biotechnology & Life Sciences | ||||||
ROE, Industry | ||||||
Health Care |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
1 2023 Calculation
ROE = 100 × Net income ÷ Shareholders’ equity
= 100 × ÷ =
2 Click competitor name to see calculations.
Profitability ratio | Description | The company |
---|---|---|
ROE | A profitability ratio calculated as net income divided by shareholders’ equity. | Vertex Pharmaceuticals Inc. ROE improved from 2021 to 2022 but then deteriorated significantly from 2022 to 2023. |
Return on Assets (ROA)
Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | ||||||
Net income | ||||||
Total assets | ||||||
Profitability Ratio | ||||||
ROA1 | ||||||
Benchmarks | ||||||
ROA, Competitors2 | ||||||
AbbVie Inc. | ||||||
Amgen Inc. | ||||||
Bristol-Myers Squibb Co. | ||||||
Danaher Corp. | ||||||
Eli Lilly & Co. | ||||||
Gilead Sciences Inc. | ||||||
Johnson & Johnson | ||||||
Merck & Co. Inc. | ||||||
Moderna Inc. | ||||||
Pfizer Inc. | ||||||
Regeneron Pharmaceuticals Inc. | ||||||
Thermo Fisher Scientific Inc. | ||||||
ROA, Sector | ||||||
Pharmaceuticals, Biotechnology & Life Sciences | ||||||
ROA, Industry | ||||||
Health Care |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
1 2023 Calculation
ROA = 100 × Net income ÷ Total assets
= 100 × ÷ =
2 Click competitor name to see calculations.
Profitability ratio | Description | The company |
---|---|---|
ROA | A profitability ratio calculated as net income divided by total assets. | Vertex Pharmaceuticals Inc. ROA improved from 2021 to 2022 but then deteriorated significantly from 2022 to 2023. |